NEC Corporation (NIPNF)
| Previous close | 71.25 |
| Open | 71.25 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 71.25 - 71.25 |
| 52-week range | 45.12 - 77.01 |
| Volume | |
| Avg. volume | 66 |
| Market cap | 19B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | 19.90 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.90 (1.27%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
- PR Newswire
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
SAP SE (NYSE: SAP) today announced NEC Corporation (TSE: 6701 "NEC") has selected SAP S/4HANA Cloud through the RISE with SAP solution, running on Amazon Web Services (AWS). Together with implementation partner ABeam Consulting, the migration will leverage NEC's generative AI technology and SAP's natural language, generative AI Joule copilot.
- PR Newswire
NEC and Sumitomo Corporation Sign Strategic Partnership Agreement to Expand Global Sales of the CropScope Agricultural ICT Platform
NEC Corporation (NEC; TSE: 6701) and Sumitomo Corporation (Sumitomo) have signed a strategic partnership agreement to expand global sales of NEC's agricultural ICT platform CropScope. Based on this partnership, NEC and Sumitomo aim to develop markets mainly in South America and the ASEAN region by utilizing Sumitomo's global network. To this end, NEC will expand the range of crops from the tomato farming support it has been focusing on and add functions to optimize and streamline a series of pro
- Business Wire
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
STRASBOURG, France & TOKYO & WALTHAM, Mass., March 05, 2024--Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies and BostonGene Corporation (BostonGene), a leading company in AI-based molecular and immune profiling, today announced the expansion of their collaboration for the randomized Phase I/II trial of TG4050, an individualized therap
